Aeterna Zentaris (NASDAQ: AEZS) announced its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.31) by $0.02. The company had revenue of $9.16 million for the quarter, compared to the consensus estimate of $7.96 million.

A number of analysts have recently weighed in on AEZS shares. Analysts at Zacks downgraded shares of Aeterna Zentaris from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, February 13th. They now have a $3.40 price target on the stock. Finally, analysts at McNicoll Lewis & Vlak upgraded shares of Aeterna Zentaris from a “hold” rating to a “buy” rating in a research note to investors on Thursday, January 3rd.

Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $5.15.

Shares of Aeterna Zentaris (NASDAQ: AEZS) traded up 0.80% during mid-day trading on Thursday, hitting $1.89. Aeterna Zentaris has a 52 week low of $1.75 and a 52 week high of $12.84. The stock’s 50-day moving average is currently $2.50. The company’s market cap is $47.9 million.

Aeterna Zentaris Inc. (NASDAQ: AEZS) is a drug development company specialized in oncology and endocrine therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.